DSIP

DSIP — Delta Sleep-Inducing Peptide — is a nonapeptide first isolated from the cerebral venous blood of sleeping rabbits in 1977 by Swiss researchers Schoenenberger and Monnier. It is named for its ability to induce delta-wave (deep) sleep in early animal experiments. Despite decades of research, the endogenous receptor and exact mechanism remain only partially characterized. It is studied for sleep architecture, stress resilience, opioid withdrawal, and pain modulation. It is sold strictly for laboratory research.

DSIP is one of the older and more mysterious research peptides — discovered in the 1970s by extracting blood from sleeping animals and identifying a fraction that promoted slow-wave sleep. The exact mechanism still isn't fully understood, which is unusual for a peptide that has been studied for almost fifty years. Online, it shows up in two main conversations: sleep optimization (for users chasing better deep sleep) and stress/withdrawal contexts (some clinical use in addiction medicine in Eastern Europe).

DSIP appears to cross the blood-brain barrier and modulate multiple neurotransmitter systems — including GABA, serotonin, and the opioid system — without binding a single well-characterized receptor. It influences corticotropin-releasing hormone (CRH) release, which may underlie its anti-stress effects. The exact downstream pathway producing increased delta-wave sleep remains an open research question.

Neuromodulatory peptide. Promotes deep slow-wave sleep cycles. Blunts cortisol.

1. DSIP
2. CNS receptor systems (melanocortin, BDNF, GABAergic or sleep-regulating)
3. Neurotransmitter and neurotrophic signalling
4. Cognition, mood, sleep and libido research endpoints

A plain-English read on how much published evidence currently exists for DSIP. These ratings describe the volume and maturity of the literature — not effectiveness, safety, or suitability for any use.

Current limitations: most compounds in this category are studied in preclinical or small-sample settings. Absence of large controlled human trials is the single biggest limitation to keep in mind when reading any summary of DSIP.

Lyophilized compounds are supplied as a dry powder. Concentration is simply the total amount in the vial divided by the volume of bacteriostatic water added:

Concentration (mg/mL) = total mg in vial ÷ mL of diluent added

Commonly supplied vial sizes

5mg vial

Worked concentration example

5mg + 2mL BAC water → 2.5mg/mL On U-100 insulin syringe:

• • 4 units = 100mcg
• • 8 units = 200mcg

Run your own numbers with the reconstitution calculator — it converts vial size and diluent volume into mg/mL and mcg/mL.

The figures below are reported here descriptively, because they are the values most frequently cited in publicly available research literature and reference material. They are not instructions, not a protocol, and not a recommendation. These compounds are supplied for laboratory research use only and are not approved by the FDA for human consumption.

Commonly cited amounts

100–200mcg before bed subcutaneous

Commonly cited frequency

Nightly as needed

Commonly cited study duration

As needed — not formally cycled

Peptides are supplied freeze-dried because peptide bonds degrade far faster in solution than in a dry state. Understanding storage is part of understanding why the powder form exists at all.

• •Lyophilized powder: stored refrigerated, typically stable for months to years.
• •Reconstituted solution: refrigerated at 2–8°C, generally discussed as stable for roughly 30–60 days.
• •Heat and direct light accelerate degradation — vials are kept cool and dark.
• •Reconstituted material is not re-frozen; ice crystal formation disrupts peptide structure.
• •Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what allows multi-day storage after reconstitution.

More detail in the storage & handling guide and how peptide quality is evaluated.

• •Sleep architecture and slow-wave sleep
• •Opioid and alcohol withdrawal in Eastern European clinical use
• •Stress and HPA axis modulation
• •Chronic pain protocols
• •Anti-oxidative effects

DSIP has a small but persistent following on sleep-focused subreddits and biohacking forums. Reports are highly variable — some users report dramatic deep-sleep improvements, others none at all. Most experienced voices note that DSIP is not a sedative; you don't feel sleepy after taking it. Instead, users describe waking up feeling more refreshed.

“The peptide that hits delta-wave sleep, not knockout sleep.”

DSIP is sometimes combined with low-dose melatonin, magnesium, or other sleep aids. It is occasionally paired with Selank for stress and sleep together. Forum protocols typically use subcutaneous injection in the evening.

DSIP is a nonapeptide discovered in 1977, studied for slow-wave sleep, stress resilience, and withdrawal applications. Its endogenous receptor is not fully characterized despite decades of research. It is sold for laboratory research only.